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Abstract
Background: Pre-eclampsia is thought to have an important genetic component. Recently, pre-
eclampsia has been associated in some studies with carriage of a common eNOS gene Glu298Asp
polymorphism, a variant that leads to the replacement of glutamic acid by aspartic acid at codon
298.
Method: Healthy women with singleton pregnancies were recruited from 7 district general
hospitals in London, UK. Women at high risk of pre-eclampsia were screened by uterine artery
Doppler velocimetry at 22–24 weeks of gestation and maternal blood was obtained to genotype
the eNOS Glu298Asp polymorphism. Odds ratios (OR) and 95%CI, using logistic regression
methods, were obtained to evaluate the association between the Glu298Asp polymorphism and
pre-eclampsia. A meta-analysis was then undertaken of all published studies up to November 2005
examining the association of eNOS Glu298Asp genotype and pre-eclampsia.
Results: 89 women with pre-eclampsia and 349 controls were included in the new study. The
Glu298Asp polymorphism in a recessive model was not significantly associated with pre-eclampsia
(adjusted-OR: 0.83 [95%CI: 0.30–2.25]; p = 0.7). In the meta-analysis, under a recessive genetic
model (1129 cases & 2384 controls) women homozygous for the Asp298 allele were not at
significantly increased risk of pre-eclampsia (OR: 1.28 [95%CI: 0.76–2.16]; p = 0.34). A dominant
model (1334 cases & 2894 controls) was associated with no increase of risk of pre-eclampsia for
women carriers of the Asp298 allele (OR: 1.12 [95%CI: 0.84–1.49]; p = 0.42).
Conclusion: From the data currently available, the eNOS Glu298Asp polymorphism is not
associated with a significant increased risk of pre-eclampsia. However, published studies have been
underpowered, much larger studies are needed to confirm or refute a realistic genotypic risk of
disease, but which might contribute to many cases of pre-eclampsia in the population.
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Background
Normal pregnancy is associated with a substantial change
in maternal cardiovascular haemodynamics. Despite an
increase in blood volume and cardiac output, blood pres-
sure falls in the first half of pregnancy, as a result of sys-
temic arteriolar vasodilatation, before returning to pre-
pregnancy levels towards term [1]. Enhanced synthesis of
the endothelium-derived mediator nitric oxide (NO),
from L-arginine by endothelial nitric oxide synthase
(eNOS), plays an important role in this vasodilatation
[2,3]. Although the role of NO in the pathogenesis of pre-
eclampsia is much debated, many studies support the
association of reduced NO availability in hypertensive
disorders of pregnancy [4,5].
Pre-eclampsia is thought to have an important genetic
component [6,7]. Several studies have reported associa-
tions between pre-eclampsia and polymorphisms of vari-
ous genes [8-10]. However, the lack of reproducibility of
genetic case-control studies has led to uncertainty about
the nature and number of genes contributing to pre-
eclampsia risk [11]. Recently, pre-eclampsia has been
associated with carriage of a common eNOS gene
Glu298Asp polymorphism, a variant that leads to the
replacement of glutamic acid by aspartic acid at codon
298. This variant is associated with reduced endothelium-
dependent vasodilatation in pregnancy [12] and has also
been associated with risk of ischaemic heart disease [13]
for which pre-eclampsia is also a risk factor [14]. However
conflicting results, mainly derived from individually
underpowered studies, have been reported [15-23].
We have undertaken a new, case-control study of the
eNOS Glu298Asp polymorphism and pre-eclampsia and
combined our results with all available studies evaluating
such an association in a meta-analysis.
Methods
Study population
Maternal genotyping was performed in women who
underwent screening by uterine artery Doppler velocime-
try at 22–24 weeks of gestation. This sub-study was part of
a multi-centre randomised controlled trial that evaluated
aspirin vs placebo as an intervention for the prevention of
pre-eclampsia and the rationale and design of the study
has been described in detail elsewhere [24]. Briefly, the
study was conducted between January 2001 and July 2002
in seven hospitals in London, UK. Transvaginal Doppler
examination of the uterine arteries was performed in
19,950 women with singleton pregnancies attending for
routine ultrasound examination at 22–24 weeks of gesta-
tion, as previously described [25]. Women with pre-exist-
ing hypertensive, cardiovascular or renal diseases,
diabetes mellitus, bleeding disorders or systemic lupus
erythematosus, multiple pregnancies and pregnancies
complicated by fetal abnormalities were excluded.
For the present study 623 women who had a mean pulsa-
tility index (PI) of the uterine arteries above the 95th cen-
tile (1.6) and 650 women with a mean PI <1.6, that
consented to give a blood sample were followed up to
delivery. Of the 1273 women, DNA was available for anal-
ysis in 89 women of the 121 who developed pre-eclamp-
sia. Baseline characteristics of the 32 women that were not
included in the DNA analysis for logistical reasons were
not significantly different from the 89 cases included in
the present report (Data not shown). Of the 1152 women
who did not develop pre-eclampsia, 349 women (ratio
1:4) were selected as controls using frequency matching
by maternal age and ethnic background.
Pre-eclampsia was defined according to the International
Society for the Study of Hypertension in Pregnancy [26].
It required two recordings of diastolic blood pressure of
90 mmHg or higher at least fours hours apart or one
recording of diastolic blood pressure of at least 120
mmHg or higher, in previously normotensive women,
and urine protein excretion of at least 300 mg in 24 hours
or two readings of 2+ or higher on dipstick analysis of
midstream or catheter urine specimens if no 24 hour col-
lection was available. The study was approved by the
Multi-Centre Research Ethics Committee as well as the
local ethics committees of the individual hospitals. Writ-
ten informed consent was obtained from all participants.
DNA extraction and genotyping
DNA was extracted by means of the QIAamp blood mini-
kit, the 894 G/T polymorphism in exon 7, which predicts
a Glu298Asp amino acid substitution in the mature pro-
tein, was genotyped by polymerase chain reaction (PCR)
with primer pairs 5'-CCCCTCCATCCCACCCAGT-
CAATCC-3' and 5'-AGGAAACGGTCGCTTCGACGT-
GCTG-3' and allele-specific restriction enzyme digestion.
PCR was performed for 35 cycles in a volume of 30 µL.
Denaturation was at 95°C, annealing at 63°C and a final
extension at 72°C, all for 45 seconds. Ten microliters of
each PCR product (151bp) was then subjected to restric-
tion digestion with 2U Dpn II, which cuts only in the pres-
ence of T-allele at position 894 (corresponding to
Asp298). Digested samples were resolved by electro-
phoresis. Genotyping was conducted in a blinded manner
to the clinical status of the subjects included in the study.
Statistical analysis
Case-control study
For the case-control study medians, proportions and their
corresponding interquartile ranges (IQR) were used for
descriptive purposes. To evaluate the presence of differ-
ences between groups unpaired Student's t, χ2, or Mann-
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Whitney tests were used as appropriate. Tests for Hardy-
Weinberg equilibrium were performed by χ2 analysis.
As an a priori hypothesis, the association between the
eNOS Glu298Asp polymorphism and pre-eclampsia was
evaluated under a recessive model of inheritance, based
on previous results from the eNOS genotype on ischaemic
heart disease risk [13]. However, additive and dominant
models were also evaluated. Multivariate analysis using
logistic regression methods was also conducted to control
for potential confounders (maternal age, ethnic back-
ground and smoking status). For each odds ratio (OR) a P
value and 95% confidence intervals (CI) were obtained.
Systematic review
Our results were then considered in the context of a meta-
analysis. Two electronic databases (MEDLINE and
EMBASE) were searched up to November 2005 for all
studies evaluating the Glu298Asp polymorphism and pre-
eclampsia in all languages. Terms used for the search were
both MeSH terms and text words "endothelial nitric oxide
synthase", "nitric oxide synthase", "pre-eclampsia", "preg-
nant hypertensive disorders" and "pregnancy hyperten-
sion" in combination with "genetic", "polymorphism(s)",
"mutation", "genotype" or "gene(s)". Authors were con-
tacted to obtain stratified data of genotype frequency by
ethnic group, and disease severity (severe vs non-severe
pre-eclampsia), and for information about the use of
blinding of genotyping staff to case-control status. The
search results were limited to "human". We searched for
any additional studies in the references of all identified
publications, and the option "related articles" in
MEDLINE for all selected papers was also used. Two inves-
tigators independently reviewed the study's eligibility,
and the inconsistencies were resolved by consensus.
Women in whom pre-eclampsia developed on the back-
ground of existing hypertension were excluded from the
present meta-analysis in order to improve the homogene-
ity of phenotype between studies. As in the case-control
study, the prior hypothesis was that homozygosity for the
Asp298 allele compared with carriers of Glu298 allele
would be associated with an increased risk of pre-eclamp-
sia. In subsidiary analyses the ORs for dominant and addi-
tive genetic models for the Glu298Asp polymorphism
were also calculated. For the additive model, a per-allele
OR of the rare allele (Asp298) was compared between
cases and controls by assigning scores of 0, 1 and 2 to
homozygotes for the common allele, heterozygotes, and
homozygotes for the rare allele, respectively, and calculat-
ing ORs by logistic regression. Pooled ORs and 95%CI
were calculated using random effect models by the
method of the DerSimonian and Laird [27,28]. The Der-
Simonian and Laird Q test [29] was used to evaluate the
degree of heterogeneity between studies, and I2 was used
as a measure to describe the percentage of variability in
point estimates that was due to heterogeneity rather than
sampling error. A visual inspection of the Funnel plot, and
the Egger regression asymmetry test were used to assess
small-study bias, of which publication bias is one poten-
tial cause [30]. Stratified analysis by predefined character-
istics, such as ethnicity, disease severity and use of
blinding of genotyping staff to case-control status were
conducted to investigate sources of heterogeneity [29].
Compliance to the Hardy-Weinberg equilibrium in the
control samples from the studies included was also evalu-
ated. Study populations were divided into Caucasians
(White-British, White-Americans, Austrians and Finnish),
Hispanics (American-Hispanics and Colombians), Afro-
Caribbean (South Africans, British of Afro-Caribbean
ancestors and Colombians of Afro-Caribbean ancestors)
and Asians (Japanese, Koreans, Bangladeshi, and British
of Indian ancestors), to analyse the effect of ethnicity on
genotype frequencies and on genotype-disease associa-
tion. A power calculation assuming that the frequency of
the genotype at risk was 8% (as reported in Caucasians)
under a recessive model of inheritance, indicated that to
detect ORs of 1.3 a total of 2800 pre-eclamptic women
and same number of controls respectively, would be
required for 80% power at significance level of 0.05 (2-
Table 1: Baseline characteristics of 438 pregnant women evaluated according to eNOS genotype
Characteristics Glu/Glu (n = 258) Glu/Asp (n = 149) Asp/Asp (n = 31) P value*
Age in years, median (IQR) 30 (24–34) 30 (26–34) 30 (22–34) 0.36
Primiparous, n (%) 135 (52) 76 (51) 20 (65) 0.38
BMI, kg/m2; median(IQR) 25.1(22.3–28.8) 25.2 (17.3–29.4) 25.9 (23.6–28.8) 0.89
Smokers, n (%) 18 (7) 15 (10) 3 (10) 0.47
Mean pulsatility index median (IQR) 1.1 (0.96–1.54) 1.1 (0.9–1.36) 0.85 (0.6–1.11) 0.68
* Comparisons between the three genotype-groups for continuous variables by ANOVA test and for categorical variables by χ2test
IQR= interquartile ranges
Glu/Glu= Glutamic acid/Glutamic acid
Glu/Asp = Glutamic/Aspartate
Asp/Asp = Aspartate/Aspartate
BMI = body mass index
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sided). Data were analysed using Stata 8.2 (Stata Corpora-
tion, College Station, Texas, 2004).
Results
Case-control study
No significant interaction between the use of prophylactic
aspirin and the genotype-outcome relationship was
observed (p = 0.85). As expected, women who developed
pre-eclampsia had a higher body mass index (26.7 vs 25,
p = 0.003) and increased mean uterine artery PI (1.85 vs
1.03, p<0.0001) compared with women who did not
developed pre-eclampsia. Baseline characteristics of the
438 women (89 pre-eclamptic and 349 controls) accord-
ing to the eNOS genotype are shown in Table 1. The dis-
tribution of the Glu298Asp genotypes in the 438 women
analysed, did not differ significantly from that expected
under the Hardy-Weinberg equilibrium (p = 0.14). No
significant difference by ethnicity was observed among
cases and controls (Caucasians: cases 51.7% and controls
57.9%; p = 0.35; Afro-Caribbean: cases 40.4 and controls
33.2%; p = 0.25; and other ethnic groups: cases 7.9% and
controls 8.9%; p = 0.93). There was no significant differ-
ence in the genotype frequencies for Glu298Asp among
cases (Glu/Glu: 60 [67%], Glu/Asp: 24 [27%] and Asp/
Asp: 5 [6%]) and controls (Glu/Glu: 198 [67%], Glu/Asp:
125 [26%] and Asp/Asp: 26 [7%]). Under a recessive
model of inheritance (Asp/Asp vs Glu/Asp plus Glu/Glu),
no significant increase risk of pre-eclampsia was observed
in a univariate (OR: 0.74 [95%CI: 0.28–1.98]; p = 0.65) or
in a multivariate model (OR: 0.83 [95%CI: 0.30–2.25]; p
= 0.70) after adjustment for potential confounders ethnic
background, smoking and maternal age. Similar results
were obtained for dominant and additive models of
inheritance (Table 2 and 3).
Meta-analysis eNOS Glu298Asp and pre-eclampsia
Twelve genetic association studies (including the present
study) of Glu298Asp polymorphism in pre-eclampsia
involving 1334 cases and 2894 controls were included in
the present meta-analysis (Table 4) [15-23,31,32]. Six of
the twelve studies, were performed only in Asians
[15,16,18,20,22,32], two only in Caucasians [17,21], one
only in Afro-Caribbeans [31] and three studies (including
the present study) conducted in a mixed population
[19,23].
The frequency in control samples of women homozygous
for the Asp298 allele was overall 3.2% (95%CI: 0.6–5.7).
However this frequency was different among ethnic
groups as follows: Caucasians 9.5% (standard error [SE]:
1.61), Asians 1.41% (SE: 0.95), Hispanics 2.55% (SE:
1.53) and Afro-Caribbean 1.11% (SE: 0.71). All control
samples from the studies included on which genotype fre-
quency was available were in Hardy-Weinberg equilib-
Table 2: Estimate of the effect of the eNOS Glu298Asp polymorphism on pre-eclampsia risk in the current case-control study 
stratified by ethnic group.
Model of inheritance Unadjusted OR (95%CI) P Adjusted OR* (95%CI) P
Additive
Asp/Asp vs Glu/Glu
All women 0.63 (0.23 – 1.72) 0.37 0.69 (0.25 – 1.92) 0.47
Caucasians 0.89 (0.30 – 2.59) 0.83 0.86 (0.29 – 2.52) 0.79
Afro-Caribbean N.A N.A
Asians N.A N.A
Glu/Asp vs Glu/Glu
0.64 (0.38 – 1.07) 0.08 0.64 (0.37 – 1.10) 0.10
Caucasians 0.77 (0.38 – 1.53) 0.46 0.78 (0.39 – 1.57) 0.50
Afro-Caribbean 0.49 (0.18 – 1.28) 0.14 0.49 (0.18 – 1.31) 0.15
Asians 0.86 (0.07 – 10.42) 0.91 0.80 (0.06 – 10.0) 0.86
Recessive
Asp/Asp vs (Glu/Asp+Glu/Glu)
All women 0.74 (0.28 – 1.98) 0.65 0.83 (0.30 – 2.25) 0.70
Caucasians 0.99 (0.35 – 2.79) 0.99 0.95 (0.34 – 2.69) 0.95
Afro-Caribbean N.A N.A
Asians N.A N.A
Dominant
(Asp/Asp+Glu/Asp) vs Glu/Glu
All women 0.63 (0.39 – 1.04) 0.07 0.65 (0.39 – 1.08) 0.09
Caucasians 0.79 (0.42 – 1.51) 0.49 0.80 (0.42 – 1.53) 0.51
Afro-Caribbean 0.46 (0.17 – 1.21) 0.11 0.45 (0.17 – 1.22) 0.11
Asians 0.52 (0.05 – 5.62) 0.59 0.51 (0.04 – 5.68) 0.58
*; ORs adjusted by maternal age, ethnic background and smoking status. In the comparisons of the eNOS genotype, the reference value for each 
comparison was set to 1.0. N.A; There were no women homozygous for the Asp-allele in the Afro-Caribbean or Asian ethnic group.
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rium (P>0.05) [15-20,22,23,31]. In two of the studies no
homozygous women were detected among cases or con-
trols [16,20] and in other study [21], the genotype fre-
quency needed for analysis under a recessive model was
not reported and the relevant information could not be
obtained from the author. Therefore, we excluded these
studies (205 cases & 510 controls) [16,20,21] for the anal-
ysis under a recessive and additive model but included
them under a dominant model of inheritance. For the
studies of Kobashi G, et al [16] and Ohta K, et al [20] a
unified data-set of tabular data obtained from the authors
was used to avoid duplication of subjects involved in the
two studies.
After combining our results in a meta-analysis, the sum-
mary OR was 1.28 (95%CI: 0.76–2.16; p = 0.34) for
women homozygous for the Asp298 allele compared with
carriers of Glu298 allele (Figure 1). No significant inter-
study heterogeneity was observed (I 2 = 27.2%, P value for
Heterogeneity [PHet] = 0.20). The distribution of the ORs
from individual studies in relation to their respective
standard deviations (the funnel plot) was symmetric and
the Egger test suggested a low probability of small-study
bias (p = 0.78).
A dominant model indicated no increase of risk of pre-
eclampsia for carriers of at least one Asp298 allele (OR:
1.12 [95%CI: 0.84–1.49]; p = 0.42) (Figure 2). There was
evidence of substantial inter-study heterogeneity (I2 =
65%; PHet = 0.001) with this model, partially explained by
ethnicity (χ2 = 17.17, 3 df, p = 0.001), while disease sever-
ity (severe vs non-severe pre-eclampsia; χ2 = 1.85, 1 df, p
= 0.17) and use of blinding of genotyping staff to the case-
control status (χ2 = 1.47, 2 df, p = 0.48) did not account
for much of the heterogeneity (Figure 3). The distribution
of the funnel plot was symmetric and the Egger test sug-
gested a low probability of small-study bias (p = 0.35).
When an additive genetic model was evaluated the sum-
mary per allele OR of the Glu298Asp polymorphism for
pre-eclampsia was 1.03 (95%CI: 0.79–1.34; p = 0.84).
The funnel plot was symmetric and the Egger test sug-
gested a low probability of small-study bias (p = 0.20).
Conclusion
The main finding of the case-control study and the meta-
analysis was that on evidence obtained to date, women
homozygous for the Asp298 allele were not associated
with a significantly increased risk of pre-eclampsia when
compared with carriers of the Glu298 allele (summary
OR: 1.28 [0.76–2.16]; p = 0.34). Similar results were
obtained using other genetic models of inheritance. How-
ever, an exploratory analysis that must be treated with
appropriate caution suggested that the effect of this candi-
date-gene might be different according to ethnic back-
ground.
The aetiology of pre-eclampsia remains complex. Identifi-
cation of candidate-genes for pre-eclampsia could aid sub-
stantially in the understanding of this important public
health problem and provide clues for the prevention and
treatment. It might also have wide relevance since women
with a history of pre-eclampsia are at increased risk of car-
diovascular disease in later life [14]. Endothelial dysfunc-
tion due to reduced NO availability has been implicated
Results of published studies of the association between the eNOS Glu298Asp polymorphism and pre-eclampsiaFig re 1
Results of published studies of the association between the 
eNOS Glu298Asp polymorphism and pre-eclampsia. ORs for 
the outcome compared homozygous women for the Asp298 
allele vs heterozygous (Glu/Asp) plus wild type (Glu/Glu) 
women (Recessive model), sorted by study size.
Table 3: Multiple regression adjusted odds ratio of pre-eclampsia.
Variable Risk Comparison Odds ratio 95% Confidence interval
eNOS/Glu298Asp Asp/Asp vs Glu-carriers 0.83 0.30 – 2.25
Smoking vs non-smokers 0.88 0.34 – 2.25
Maternal age per 1 year increment 1.02 0.98 – 1.06
Ethnic group Caucasians 0.75 0.45 – 1.25
Asians vs Afro-Caribbean 1.06 0.39 – 2.89
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Table 4: Characteristics of published studies of the association between the eNOS genotype (Glu298Asp) and pre-eclampsia included 
in the meta-analysis
Study-year 
(Country)
Study 
design
Matching Asp/Asp * 
genotype 
(%)
Primiparous 
(%) Cases 
Controls
Proteinuria 
threshold
Systolic/
Diastolic 
blood 
pressure 
threshold
Main exclusion criteria
Caucasians
Hakli T-2003 
(Finland)
Case-control Age 10.61 100 -- 0.3 g/24 h 140/90 • Hypertension
Tempfer CB-
2004‡ 
(Austria)
Case-control Gestationa
l age and 
parity
-- -- -- 5 g/24 h 160/110 • Cardiac (Hypertension), diabetes 
mellitus or renal disease
• Multiple pregnancies
• Autoimmune disorders & history 
of recurrent miscarriage
Oriental
Yoshimura T-
2000 (Japan)
Case-control Age 1.17 68.7 80 0.3 g/L 140/90 • Cardiac, diabetes mellitus or renal 
disease
• Lupus erythematosus
• Multiple pregnancies
Kobashi G-
2001 (Japan)
Case-control -- 0 59.2 57 0.3 g/L 140/90 • Hypertension, diabetes mellitus or 
renal disease
• Multiple pregnancies
• Amniotic volume abnormalities or 
fetal anomalies
Watanabe H-
2001‡ (Japan)
Case-control -- 3.12 -- -- 2 g/24h 160/110 • Hypertension
• Renal disease
Ohta K-2004‡ 
(Japan)
Case-control -- 0 100 100 2 g/24 h 160/110 • Hypertension, diabetes mellitus, 
renal disease
• Multiple pregnancies
• Amniotic volume abnormalities or 
fetal anomalies
Kim YJ 
(Korea)
Case-control -- -- 21 31 0.3 g/L 140/90 • Hypertension, diabetes mellitus or 
renal disease
• Multiple pregnancies, recurrent 
miscarriages, fetal growth 
retardation or abruption placenta
Asians
Yoshimura T-
2003‡ 
(Bangladesh)
Case-control Age 3.36 44.6 51.2 ≥ 3+ dipstick 160/110 • Hypertension, Diabetes mellitus or 
renal disease
• Lupus erythematosus
• Multiple pregnancies
Afro-Caribbeans
Hillermann 
R‡ (South 
Africa)
Case-control -- 1.19 100 -- 0.3 g/L --/90 • Hypertension, diabetes mellitus, 
renal disease
Study-year 
(Country)
Study 
design
Matching Asp/Asp * 
genotype 
(%) 
Primiparous 
(%) Cases 
Controls
Proteinuria 
threshold
Systolic/
Diastolic 
blood 
pressure 
threshold
Main exclusion criteria
Mixed population†
Landau R-
2004 (United 
States)
Case-control -- 5.03 55 41 0.3 g/L 140/90 • Hypertension
Yu C. KH-
2004 (United 
Kingdom)
Case-control -- 7.44 56.3 69.3 0.3 g/24 h 140/90 • Cardiac, diabetes mellitus or renal 
disease
• Lupus erythematosus
• Multiple pregnancies
Serrano NC-
2004 
(Colombia)
Case-control -- 1.14 100 100 0.3 g/24 h 140/90 • Cardiac (Hypertension), diabetes 
mellitus or renal disease
• Multiple pregnancies
• Lupus erythematosus
*; Genotype frequency from control subjects. ‡ Studies in which only women with severe pre-eclampsia were included as cases.
†; Landau R included Hispanic and White American women, Yu C.KH included Caucasian, Afro-Caribbean, and Asian women and Serrano N 
included Hispanic and Afro-Caribbean women.
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as potentially important mechanism in both pre-eclamp-
sia [33] and cardiovascular disease [34].
Pre-eclampsia has an inherited component and it is likely
that many genes are involved [35]. Previous linkage stud-
ies in affected siblings pairs have implicated the eNOS
gene locus on chromosome 7q35 to 36 [36,37]. The com-
mon Asp298 variant of the eNOS might be susceptible to
enhanced proteolytic cleavage [38,39] and this could con-
tribute to the abnormally low NO production and
increased cardiovascular risk observed in carriers of this
allele, [13,39] though these findings have been debated
[40]. These results have been supported by human studies
that have reported that healthy pregnant women carriers
of the Glu298Asp polymorphism have impairment in the
flow mediated dilation, an indirect tool to evaluate NO
bioavailability [12]. Although, it has been suggested that
carriers of this allele might be more susceptible to
endothelial dysfunction and hence the subsequent devel-
opment of pre-eclampsia [33], in the present report we
failed to detect a significant positive association between
the Glu298Asp polymorphism and pre-eclampsia.
The lack of evidence of increased pre-eclampsia risk for
the eNOS Glu298Asp variant may be explained by: (i) the
absence of a biological effect, (ii) failure to detect a small
but important increase in susceptibility to pre-eclampsia
because of inadequate statistical power or (iii) the pres-
ence of real genetic heterogeneity according to ethnic
background (a significant genotype-disease association in
some, but not all ethnic groups). It has been recently sug-
gested, that for complex diseases with a low sibling recur-
rence risk such as pre-eclampsia, several candidate-genes
with a small to moderate effect, rather than a few candi-
date-genes with a high effect on incidence of the disease,
is the more likely model to explain such genetic suscepti-
bility [11]. This suggestion has been recently supported,
for findings in other complex disease like ischaemic stroke
where in a systematic analysis of all candidate-genes eval-
uated thus far, just a few genes with a small to moderate
effect (ORs between 1.2 and 1.45) were shown to exhibit
a significant association with the disease[41].
In order to increase the statistical power, we therefore
combined all available studies in a meta-analysis. In addi-
tion to our study, eleven other studies were identified, but
only nine studies providing 3513 women (1129 cases &
2384 controls) under a genetic recessive model were
included in our main comparison. A very large case-con-
trol study or a meta-analysis of smaller studies, including
about 5600 Caucasian women would be needed to have
an 80% of power at a significance level of 5% to detect an
OR of 1.3 under a recessive model of inheritance. A sam-
ple size approximately three times higher would be
needed to detect the same OR among non-Caucasian pop-
ulations because of the lower allele frequency of Asp298.
Thus, a small to moderate effect on incidence of pre-
eclampsia for the Glu298Asp cannot be totally excluded
on current evidence. Since recruitment of data sets of the
required size may be difficult "de novo" for a single centre,
Sensitivity analysis of the Glu298Asp polymorphism and pre-eclampsia Summary odds ratio for re-eclampsia for women carrier  of the Asp298 allele compared to women homozygous for the Glu298 allele, divided by eth ic gr up, disease severit  nd blinding f the g notyping staffFigur  3
Sensitivity analysis of the Glu298Asp polymorphism and pre-
eclampsia Summary odds ratio for pre-eclampsia for women 
carriers of the Asp298 allele compared to women 
homozygous for the Glu298 allele, divided by ethnic group, 
disease severity and blinding of the genotyping staff.
Results of published studies of association between the Glu298Asp po ymorphism and pre-eclampsiaFig re 2
Results of published studies of association between the 
Glu298Asp polymorphism and pre-eclampsia. ORs for the 
outcome compared women carriers for the Asp298 allele vs 
women homozygous for the Glu298allele (Dominant model), 
sorted by study size.
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an alternative approach, which has been suggested in the
cardiovascular arena, involves the recruitment and geno-
typing of smaller numbers of patients and controls from
many centres according to uniform selection criteria and
outcome definitions, and submission of the data to a
common web-based repository for on line continuously
up-dated meta-analysis. Such an approach would also
help to minimise publication bias, which is a potential
concern with meta-analysis of published genetic associa-
tion studies. However, an alternative approach would be
to conduct a very large multi-centre case-control study of
several thousand of cases, which should be less prone to
bias, in order to confirm or refute the role of candidate
gene-variants with small to moderate effects in pre-
eclampsia [11].
In summary, currently available data from genetic associ-
ation studies do not provide positive evidence for a role of
the eNOS Glu298Asp polymorphism in pre-eclampsia.
Very large studies, in both Caucasians and non-Caucasian
subjects, are required before a role for this gene can be
excluded, and the development of very large datasets is an
important research priority for genetic studies in this area
[42].
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